WILMINGTON, DE — Incyte (Nasdaq: INCY) will present new clinical and preclinical data across its hematology and oncology pipeline at the 2026 European Hematology Association Congress, as the drugmaker seeks to expand regulatory approvals and strengthen its position in blood cancer and myeloproliferative disease markets.
The presentations, scheduled for the June 11-14 conference in Stockholm, include data tied to regulatory submissions for tafasitamab in first-line diffuse large B-cell lymphoma and advancing Phase 3 development programs for experimental myeloproliferative neoplasm therapies.
The company identified results from the Phase 3 frontMIND study of tafasitamab in combination with lenalidomide and R-CHOP chemotherapy as a key presentation during the conference’s plenary abstract session.
Monjuvi, marketed as Minjuvi in Europe, is already approved in certain relapsed or refractory lymphoma settings. The new front-line diffuse large B-cell lymphoma data could expand the drug’s commercial reach if regulators approve broader use in the United States and Europe.
“The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” Pablo J. Cagnoni, Incyte’s president and global head of research and development, stated in the announcement.
The company also plans multiple presentations involving INCA033989, an experimental monoclonal antibody targeting mutant calreticulin-linked myeloproliferative neoplasms, including myelofibrosis and essential thrombocythemia.
According to Incyte, the therapy demonstrated spleen, anemia, hematologic, and molecular responses in early-stage studies while maintaining what the company described as a favorable tolerability profile.
Additional presentations will cover experimental therapies including INCA035784 and INCB160058, as well as studies involving Axatilimab, Ponatinib, Ruxolitinib, and tafasitamab in follicular lymphoma and chronic graft-versus-host disease.
The conference data arrive as oncology drugmakers intensify competition in hematologic cancers, particularly in targeted therapies and biologics aimed at genetically defined blood disorders and lymphoma subtypes.
Incyte stated several of the presentations support ongoing late-stage development programs and future regulatory strategies tied to its hematology portfolio.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.